Skip to main content

MPM BioVentures 2014, L.P.'s Form 4 filing

Werewolf Therapeutics, Inc. (HOWL) · filed Dec 4, 2025

Accession no.
0001231919-25-000575
Filed
Dec 4, 2025, 6:19 PM ET
Trade date
Dec 2-4, 2025
Filing delay
2 days
Rule 10b5-1 plan
Checked

This filing lists 3 non-derivative transactions. Open-market sales total $183.3K. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
MPM BioVentures 2014, L.P.CIK 0001609492Other: Former 10% Owner
MPM BioVentures 2014 (B), L.P.CIK 0001609493Other: Former 10% Owner
MPM Asset Management Investors BV2014 LLCCIK 0001609495Other: Former 10% Owner
MPM BioVentures 2014 LLCCIK 0001765021Other: Former 10% Owner
MPM BioVentures 2014 GP LLCCIK 0001765091Other: Former 10% Owner

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Dec 2, 2025Common StockSSaleDisposed−59,277$0.89F3−$52,756.534,924,566IndirectDuplicate filing
Dec 3, 2025Common StockSSaleDisposed−57,225$0.87F7−$49,785.754,867,341IndirectDuplicate filing
Dec 4, 2025Common StockSSaleDisposed−83,230$0.97F10−$80,733.14,784,111IndirectDuplicate filing

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F3

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.852 to $0.9246 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Referenced by the price of 1 transaction in Table I.

F7

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.82 to $0.9256 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Referenced by the price of 1 transaction in Table I.

F10

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.92 to $1.0208 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Referenced by the price of 1 transaction in Table I.

Remarks

This filing is 1 of 2 identical filings due to limitations on number of Reporting Persons. See Form 4 filed by Ansbert Gadicke.

Read the full filing on SEC EDGAR (opens in a new tab)